|Articles|December 2, 2013
Lilly Strategy: Timely, Valued Medicines to Patients
Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company?s new approach to drug development and its Phase III pipeline.
Advertisement
Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company’s new approach to drug development and its Phase III pipeline.
For more videos tune in to:
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
2
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
3
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung
4
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
5